Farbstein Motti 4

4 · Can-Fite BioPharma Ltd. · Filed Jun 8, 2026

AI-generated summary of this filing

Updated Jun 8, 2026

Can‑Fite (CANF) CEO/CFO/COO Motti Farbstein Receives Options (24,000)

What happened

Motti Farbstein, who serves as Can‑Fite BioPharma's CEO, CFO and COO, was granted a derivative award of 24,000 options (reported as acquisition at $0.00) on June 4, 2026. This is an option grant rather than a cash purchase or sale; the exercise price was originally NIS 5.94 (converted to approximately USD $2.04 using the Bank of Israel rate on 06/05/2026).

Key details

Transaction date: 2026-06-04; Form 4 filed: 2026-06-08 (timely within the 2-business-day window).
Award size: 24,000 options; reported acquisition price: $0.00 (derivative award).
Exercise price: NIS 5.94 → ≈ USD $2.04 (conversion rate NIS 2.908 = USD 1.00 on 06/05/2026).
Vesting: 16 equal quarterly installments beginning 09/04/2026 and ending 04/06/2030, contingent on continued service.
Trustee registration: For certain Israeli tax benefits, securities under Can‑Fite’s option plans must be registered in the name of a trustee (per filing footnote).
Shares owned after transaction: Not specified in the provided filing excerpt.

Context

This filing documents an option grant (award). Because no exercise or sale occurred, it does not represent an immediate cash outlay or liquidity event. Vesting is spread over ~3.5 years, so these options become exercisable gradually subject to continued employment.

Form 4

Period: 2026-06-04

CEO, CFO and COO

Transactions

Award
Options to Purchase Ordinary Shares
[F1][F2][F3]
2026-06-04+24,000→ 33,132 total
Exercise: $2.04From: 2026-09-04Exp: 2036-06-04→ Ordinary Shares (24,000 underlying)

Footnotes (3)

[F1]To qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance, securities issued to an employee in connection with the Issuer's 2003 Share Option Plan, 2013 Share Option Plan and 2023 Share Option Plan must be registered in the name of a trustee.
[F2]The options will vest in sixteen equal quarterly installments beginning 09/04/2026 and ending 04/06/2030, subject to the Reporting Person's continued service to the Issuer as of such vesting date.
[F3]The exercise price of this option, originally denominated in New Israeli Shekels ("NIS") in the amount of NIS 5.94, is presented in the table in U.S. dollars ("USD") based on the exchange rate reported by the Bank of Israel on June 5, 2026, which was NIS 2.908 = USD 1.00.

Signature

/s/ Motti Farbstein|2026-06-08

1 file